| Literature DB >> 35347235 |
Ming Zou1, Qin Ke1, Qian Nie1, Ruili Qi1, Xingfei Zhu1, Wei Liu1, Xuebin Hu1, Qian Sun1, Jia-Ling Fu1, Xiangcheng Tang1, Yizhi Liu1, David Wan-Cheng Li2, Lili Gong3.
Abstract
Atrophic ("dry") form of age-related macular degeneration (AMD) is a leading cause of vision loss characterized by macular retinal pigment epithelium (RPE) and the ensuing photoreceptor degeneration. cGAS-STING signaling is a key cytosolic DNA sensor system in innate immunity and have recently been shown promotes RPE degeneration. However, expression regulation and therapeutic potential of cGAS and STING are not explored in retina under dry AMD pathogenic conditions. Our analysis shows upregulated STING RNA and increased chromatin accessibility around cGAS and STING promoters in macular retinas from dry AMD patients. cGAS-STING activation was detected in oxidative stress-induced mouse retina degeneration, accompanied with cytosolic leakage of damaged DNA in photoreceptors. Pharmaceutical or genetic approaches indicates STING promotes retina inflammation and degeneration upon oxidative damage. Drug screening reveals that BRD4 inhibitor JQ1 reduces cGAS-STING activation, inflammation and photoreceptor degeneration in the injured retina. BRD4 inhibition epigenetically suppresses STING transcription, and promotes autophagy-dependent cytosolic DNA clearance. Together, our results show that activation of cGAS-STING in retina may present pivotal innate immunity response in GA pathogenesis, whereas inhibition of cGAS-STING signaling by JQ1 could serve as a potential therapeutic strategy.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35347235 PMCID: PMC9433402 DOI: 10.1038/s41418-022-00967-4
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 12.067
Fig. 1STING is elevated in macular retina of dry AMD patients and cGAS-STING signaling is activated during mouse retina degeneration.
A Gene set enrichment analysis (GSEA) profiles showing significant enrichment of gene sets associated with indicated pathway in dry AMD retinas (n = 41) compared to normal retinas (n = 55) (GSE29801) [24]. The false discovery rate (FDR) < 0.25 for pathways mentioned. B RNA-seq analysis of STING expression in extra-macular and macular retinas of normal (n = 26) and dry AMD patients (n = 20) [24]. Comparisons were made between retinas from normal and dry AMD patients (unpaired t-test), and the extra-macular and macular retinas of the same eye (paired t-test). C–J Mice were intraperitoneal (IP) injected with PBS or sodium iodate (SI) (35 mg/kg) and analysis was conducted 3-day post injection otherwise indicated. C Fundus photography (a, b) and fluorescein angiography (c, d) showing eye morphology. RPE flat mounts stained with phallodin-FITC to label the F-actin (e, f) and with IBA1 antibody to label the mononuclear phagocytes (MP) (g, h). Scale bar: 20 μM. (n = 3). (i, j) Immunohistochemistry (IHC) showing IBA1-positive MP in retina sections. Scale bar: 50 μM (n = 2). D Upper panels: Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis showing cell death. Arrow head: TUNEL-positive RPE cells. Lower panels: Hematoxylin and eosin (HE) staining. (n = 3) H: hour, D: day. Scale bar: 50 μM. Western blot (WB) analysis showing retina proteins at the indicated time (E) or 3-day (F, G) post injection. Right panels: quantification results of WB. M month. H qRT-PCR analysis of retina RNA 3-day post injection. I WB showing retina proteins. Right panels: quantification results of WB. J IHC analysis using rhodopsin antibody shows retina structure 1-day post SI injection. Arrows indicated destruction of photoreceptors. (n = 3). Scale bar:100 μM.
Fig. 2STING promotes retina inflammation upon oxidative injury.
A HE staining of mouse retina. Subretinal bleeding was observed in retinas from 4 out of 6 diABZI-injected mice. Scale bar: 100 μM. B IF analysis showing IBA1-positive MPs. Note that diABZI alone increased MP infiltration around the optic nerve. Right panel: quantification of IBA1-positive cells. Scale bar: 200 μM. WB (C) or qRT-PCR (D) showing indicated retinal proteins or gene expression. WB (E) or qRT-PCR (F) showing indicated retinal proteins or gene expression. G HE staining of mouse retina. Arrows indicate retina disorganization and arrow heads indicate swelling and bundling of RPE cells. Scale bar: 200 μM. H IF analysis showing IBA1-positive MPs in retina. Arrows: destructive retina, arrow heads: subretinal localization of MPs. n = 4. Scale bar: 200 μM. I IF analysis shows IBA1-positive MPs in RPE flat mounts. n = 4. Scale bar: 500 μM. Right panel: IBA1-positive cell number in four randomly selected regions. J WB showing indicated proteins in ARPE-19 cells. Cells were exposed to 600 μM H2O2 for 2 h and recovered for 2 h before analysis.
Fig. 3OS-induced DNA damage and cytosolic leakage provoke retinal cell inflammation.
Immunofluorescence (IF) staining for dsDNA A and dsDNA/rhodopsin B in retina. The DNA was counterstained with DAPI. Scale bar: 200 μM. C Schematic diagram for preparation of nuclei- and mitochondria-free retinal cytosol. D WB showing separation of retina nuclear and cytosolic fractions. E q-PCR analysis of cytosolic nuclear and mitochondrial (Mito) DNA. F, G IF staining in 661W cells using the indicated antibodies. Arrows: cytosolic DNA with positive γH2Ax labeling. Scale bar: 5 μM. WB showing retina proteins at the indicated time points (H) or 3-day (I) post SI injection. J WB showing indicated proteins in 661W cells. Cells were treated with or without Ara-C (10 μM) and collected at the indicated time points. K, L qRT-PCR analysis showing gene expression in ARPE cells. Cells were treated with DMSO or NAC (1 mM) or MitoQ (1 μM) for 24 h before collection. M, N WB analysis showing protein expression. M 661W cells were untreated (Ctrl) or, transfected with lipofectamine or linearized GFP-C3 plasmid (1 ug/ml) and harvested at the indicated time points. N ARPE cells were transfected with lipofectamine (Ctrl), or genomic DNA isolated from normal (nor-gDNA) or H2O2-exposred (H2O2-gDNA) ARPE or 661W cells (2 ug/ml) and collected 16 h post transfection. O qRT-PCR analysis showing indicated genes in ARPE cells transfected with or without ARPE genomic DNA as described as Fig. 6N.
Fig. 6OS-induced BRD4 promotes STING expression and inflammation.
A Heat map depicting upregulated genes involved in inflammatory response in OS-exposed ARPE cells (p < 0.05, with 1.5-fold change) [40]. B–D WB analysis showing induction of BRD4 upon OS. B 661W cells were treated with or without 600 μM H2O2 for 2 h and recover for 1 day before analysis. Mouse retinas were collected at the indicated time points (C) or 3 days (D) after SI injection for WB. qRT-PCR (E) or WB (F) analysis in ARPE cells. G, H Live/dead cell viability assay shows dead (red) and live (green) ARPE cells. For H2O2 treatment, 1.8 mM used in G and 0.6 mM used in H. I Relative ROS levels in ARPE cells. ROS levels were normalized by reads from cell counting kit-8 assay. J–L qRT-PCR showing gene expression in ARPE cells. After transfection, cells were treated with or without H2O2 (0.6 mM, 2 h) (K), or NAC (1 mM) or MitoQ (1 μM) for 6 h before analysis. M Schematic diagram summarizes OS-induced BRD4 activates STING and inflammation.
Fig. 4BRD4 inhibitors repress STING expression and STING-mediated NFκB activation.
A Schematic diagram shows drug screening process. The red triangles represent identified BRD4 inhibitors. B Representative images from high-content analysis. Arrow heads: γH2Ax-positive cytosolic DNA. Right panel: relative cytosolic DNA number after normalized to nuclei numbers, 30–50 cells counted. WB or qRT-PCR analysis showing protein C or gene D expression in ARPE-19 cells. Selection of other small molecules in WB was based on results from high-content analysis. Treatment conducted as described in A. WB E or qRT-PCR F analysis conducted in 661W treated with or without 10 μM of JQ1 for 24 h.
Fig. 5BRD4 inhibitors epigenetically represses STING transcription.
A, B qRT-PCR analysis for gene expression. The detailed treatment was described in “Methods” section. C ATAC-Seq shows chromatin accessibility in the indicated genes. (macular: n = 5 for normal, n = 2 for early dry AMD, n = 5 for GA; peripheral macular: n = 6 for normal, n = 4 for early dry AMD, n = 4 for GA) [37]. D Micrococcal nuclease digestion assay shows chromatin compaction in 661W cells. Treatment was the same in B. TSS transcription start site. E Epigenetic profiles of STING in mouse macrophage treated with 5 μM of I-BET762 (+) or DMSO (−). Original data from published ChIP-Seq [39]. The y-axes represent the average number of tags per gene per 25 base pairs per 1,000,000 mapped reads. Scale values are indicated in parentheses. F WB analysis of retina proteins in the indicated treatment. G ChIP assay shows association of the indicated proteins with the STING.
Fig. 7JQ1 inhibits cGAS-STING activation and retina degeneration after SI injury.
WB (A, B, D) and qRT-PCR (C) analysis of indicated protein or gene expression. IF showing IBA1-postive cells in retina cryosections (E) and retina flat mounts (F). Right panels: quantification results of IBA1-positive cells in 10 (E) or 15 (F) randomly selected regions. Scale bar: 200 μM, n = 3. G RPE flat mounts were stained with IBA1 and FITC Phalloidin to label F-actin. Scale bar: 100 μM. Right panels: quantification results of IBA1-positive cells in five randomly selected regions. H IHC analysis of the mouse retina. n = 4. Scale bar: 100 μM. I Fundus photography (upper panels) and fluorescein angiography (lower panels) analysis. n = 4.
Fig. 8BRD4 inhibition promotes autophagy-dependent clearance of cytosolic DNA.
A IF analysis showing cytosolic dsDNA in retina photoreceptors. Scale bar: 200 μM. WB analysis showing indicated proteins in 661W cells (B) or ARPE cells (C, D). E Live cell imaging showing JQ1 promoted exogenous cytosolic dsDNA clearance. Cy3- DNA was transfected into ARPE LC3-GFP cells and live cell imaging was performed 6 h after transfection with or without the addition of JQ1 (1 or 10 μM). The still frames were indicated at the indicated time points. Lower panel: mean fluorescence intensity of Cy3-dsDNA calculated from live cell images using ImageJ from 20 different fields. F IF for dsDNA in 661W cells. Scale bar: 50 μM. Lower panels: the relative cytosolic dsDNA foci number and area in the intact nuclei were calculated from six randomly selected fields. G IF analysis showing dsDNA and DNA damage. Scale bar: 20 μM. Lower panel: relative cytosolic DNA number after normalized to nuclei numbers. For each group, 30–50 cells were counted. H, I qRT-PCR analysis showing indicated gene expression in ARPE cells. JQ1 (10 μM), and or CQ (10 μM) were added 6 h after transfection.
Key reagents and resources used in this study.
| Reagent or resource | Source | Identifier |
|---|---|---|
| Antibodies | ||
| STING (D1V5L) Rabbit mAb (Rodent Preferred) | Cell Signaling Technology | cat#50494 |
| Phospho-STING (Ser365) (D8F4W) Rabbit mAb | Cell Signaling Technology | cat#72971 |
| cGAS (D3O8O) Rabbit mAb (Mouse Specific) | Cell Signaling Technology | cat#31659 |
| TBK1/NAK (D1B4) Rabbit mAb | Cell Signaling Technology | cat#3504 |
| Phospho-TBK1/NAK (Ser172) (D52C2) XP® Rabbit mAb | Cell Signaling Technology | cat#5483 |
| IRF-3 (D83B9) Rabbit mAb | Cell Signaling Technology | cat#4302 |
| Phospho-IRF-3 (Ser396) (D6O1M) Rabbit mAb | Cell Signaling Technology | cat#29047 |
| Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb | Cell Signaling Technology | cat#3033 |
| NF-κB p65 (D14E12) XP® Rabbit mAb | Cell Signaling Technology | cat#8242 |
| IL-1β (3A6) Mouse mAb | Cell Signaling Technology | cat#12242 |
| Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb | Cell Signaling Technology | cat#9718 |
| GAPDH (D16H11) XP® Rabbit mAb | Cell Signaling Technology | cat#5174 |
| Acetyl-Histone H3 (Lys9) (C5B11) Rabbit mAb | Cell Signaling Technology | cat#9649 |
| Histone H3 (D1H2) XP® Rabbit mAb | Cell Signaling Technology | cat#4499 |
| Phospho-IRF-7 (Ser437/438) (D6M2I) Rabbit mAb (Mouse Specific) | Cell Signaling Technology | cat#24129 |
| Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) | Cell Signaling Technology | cat# 4412 |
| Anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 594 Conjugate) | Cell Signaling Technology | cat# 8890 |
| Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 594 Conjugate) | Cell Signaling Technology | cat# 8889 |
| Rabbit monoclonal [EPR16588] to IBA1 | Abacm | cat#ab178846 |
| Rabbit polyclonal to Histone H3 (tri methyl K9) | Abacm | cat#ab8898 |
| Rabbit polyclonal to RNA polymerase II CTD repeat YSPTSPS (phospho S2) | Abacm | cat#ab5095 |
| Rabbit polyclonalto Brd4 | Abacm | cat# ab84776 |
| Rabbit polyclonal to LC3B | Abacm | cat# ab48394 |
| Rabbit polyclonal to SQSTM1 / p62 | Abacm | cat#ab155686 |
| p-Histone H2A.X (Ser 139) anti-mouse | Santa Cruz Biotechnology | cat#sc-517348 |
| dsDNA Marker (HYB331-01) | Santa Cruz Biotechnology | cat#sc-58749 |
| Antibody anti-rabbit IRF-7 antibody(F-1) | Santa Cruz Biotechnology | cat#sc-74471 |
| 8-OHdG antibody (E-8) | Santa Cruz Biotechnology | cat# sc-393871 |
| TMEM173/STING Antibody | Proteintech | cat#66680-1 |
| GAPDH Mouse Monoclonal Antibody | Proteintech | cat#60004-1 |
| beta Tubulin Mouse Monoclonal Antibody | Proteintech | cat#66240-1 |
| TFAM Rabbit Polyclonal Antibody | Proteintech | cat# 22586-1 |
| Alpha Actinin Polyclonal antibody | Proteintech | cat# 11313-2 |
| Polyclonal Rabbit Anti- Glial Fibrillary Acidic Protein (GFAP) | Dako | cat#Z0334 |
| Rhodopsin | ShuYi Chen Lab | cat#Mm53356 |
| Phospho-Brd4(Ser492/Ser494) | Merck Millipore | cat# ABE1453 |
| Rabbit anti-53BP1 Antibody | Bethyl | cat#A300-272A |
| FITC Phalloidin | Yeasen | cat# 40735ES75 |
| Recoverin Antibody anti-rabbit | EMD Millipore | cat#AB5585 |
| Chemicals, peptides, and recombinant proteins | ||
| diABZI STING agonist (compound 3) (diABZI STING agonist (compound 3) | Selleck | cat#S8796 |
| JQ1 | Selleck | cat#S7110 |
| Birabresib (OTX015) | Selleck | cat#S7360 |
| Molibresib (I-BET-762) | Selleck | cat#S7189 |
| PFI-2 HCl | Selleck | cat#S7294 |
| MS436 | Selleck | cat#S7294 |
| Cerdulatinib (PRT062070) | Selleck | cat#S7634 |
| Remodelin | Selleck | cat#S7641 |
| Bafilomycin A1(BafA1) | Selleck | cat#S1413 |
| Mitoquinone | Selleck | cat#S8978 |
| Acetylcysteine (N-acetylcysteine) | Selleck | cat#S1623 |
| Chloroquine | Selleck | cat#S6999 |
| PEG300 | Selleck | cat# S6704 |
| cGAMP | Macklin | cat#G877072 |
| DMSO | MP Biomedicals | cat#196055 |
| Sodium iodate | Sigma-Aldrich | cat#S4007 |
| Cy3-X-dUTP | ABP Biosciences | cat#C419 |
| Hieff TransTM Liposomal transfection reagent | Yeasen | cat#40802ES03 |
| Epigenetics Compound Library | Selleck | cat#L1900-Z308784 |
| Experimental models: cell lines | ||
| ARPE-19 | ATAC | |
| 661W | Huangxuan Shen Lab | N/A |
| human primary RPE cells | This study | N/A |
| Experimental Models: Organisms/Strains | ||
| Mouse: C57BL/6: C57BL/6J | Sun Yat-Sen University | C57BL/6J |
| Laboratory Animal Center | ||
| Deposited data | ||
| ATAC-seq Data | Gene Expression Omnibus | GSE99287 |
| RNA Microarray Data | Gene Expression Omnibus | GSE29801 |
| ChIP-seq Data | Gene Expression Omnibus | GSE21910 |
| Software and algorithms | ||
| GraphPad Prism 7.0 | GraphPad software | |
| ImageJ 1.46/ Fiji | NIH | |
| IGV_2.8.2 | Integrative Genomics Viewer | |
| SRA Tools | NCBI | |
| Trim Galore | Babraham Institute | |
| SAMTools | Li et al. [ | |
| Sambamba | Tarasov et al. [ | |
| MACS2 | N/A | |
| deepTools | Ramírez et al. [ | |
Primers used for qRT-PCR, qCHIP, MNase assay and mitochondria and nuclear DNA detection.
| Primer for specific gene | Primer direction | Primer sequence |
|---|---|---|
| Human IL1β | F | CTCGCCAGTGAAATGATGGCT |
| Human IL1β | R | GTCGGAGATTCGTAGCTGGAT |
| Human IL6 | F | GTGAAAGCAGCAAAGAGGC |
| Human IL6 | R | TTTCACCAGGCAAGTCTCC |
| Human IL8 | F | TTGGCAGCCTTCCTGATTT |
| Human IL8 | R | AACTTCTCCACAACCCTCTGC |
| Human IFNB | F | GCTCTCCTGTTGTGCTTCTCC |
| Human IFNB | R | CCTCCTTCTGGAACTGCTGC |
| Human cGAS | F | ACGTGCTGTGAAAACAAAGAAG |
| Human cGAS | R | GTCCCACTGACTGTCTTGAGG |
| Human STING | F | ATATCTGCGGCTGATCCTGC |
| Human STING | R | GGTCTGCTGGGGCAGTTTAT |
| Human GAPDH | F | GAAGGTGAAGGTCGGAGT |
| Human GAPDH | R | GAAGATGGTGATGGGATTTC |
| Mouse IL1β | F | TGCAGACTCAAACTCC |
| Mouse IL1β | R | TGAAAGACGGCACACC |
| Mouse IL6 | F | GTTCTCTGGGAAATCGTGG |
| Mouse IL6 | R | CTGCAAGTGCATCATCGTT |
| Mouse IFNB | F | CTCCAGCTCCAAGAAAGGAC |
| Mouse IFNB | R | TGGCAAAGGCAGTGTAACTC |
| Mouse cGAS | F | GGAAGGAACCGGACAAGCTA |
| Mouse cGAS | R | AACTCCGACTCCCGTTTCTG |
| Mouse STING | F | GGAACACCGGTCTAGGAAGC |
| Mouse STING | R | TGGATCCTTTGCCACCCAAA |
| Mouse mitochondria | F | CTAGAAACCCCGAAACCAAA |
| Mouse mitochondria | R | CCAGCTATCACCAAGCTCGT |
| Mouse B2M | F | ATGGGAAGCCGAACATACTG |
| Mouse B2M | R | CAGTCTCAGTGGGGGTGAAT |
| Mouse ACTIN | F | CCTAAGGCCAACCGTGAAAA |
| Mouse ACTIN | R | CAGAGGCATACAGGGACAGC |
| Mouse GAPDH promoter | F | CCACTTGTGGCAAGAGGCTA |
| Mouse GAPDH promoter | R | GTGGAGAGTTGGGACGTGAG |
| Mouse cGAS (MNase)#1 | F | AGGAGCAAAATTCACTGCGA |
| Mouse cGAS (MNase)#1 | R | CCCACAGGTGATGCTAAGAG |
| Mouse cGAS (MNase)#2 | F | TGGAATAGGCATGAGCATCG |
| Mouse cGAS (MNase)#2 | R | GTCGCAGTGAATTTTGCTCC |
| Mouse cGAS (MNase)#3 | F | TCGGTGTCTTTTTATTCAGGCT |
| Mouse cGAS (MNase)#3 | R | TGCAATCCTGTGTGTCCCTT |
| Mouse cGAS (MNase)#4 | F | TTGGCTGCTGAGATTCCGTA |
| Mouse cGAS (MNase)#4 | R | GCAAAATGAGTTCCGCCAAG |
| Mouse cGAS (MNase)#5 | F | GGTTTACAGTGAGTCCCAGGAC |
| Mouse cGAS (MNase)#5 | R | TGGCTAGATTTGCCGCCTAC |
| Mouse STING (MNase)#1 | F | CGTTTAAAGAGCCAGGCAGTG |
| Mouse STING (MNase)#1 | R | TGGATTGTGGTCTGCACGTT |
| Mouse STING (MNase)#2 | F | CAGATGGCTAGCAGGGAAGAG |
| Mouse STING (MNase)#2 | R | GGAGGGCACCGGACAATTTAT |
| Mouse STING (MNase)#3 | F | TTTCGGGGAAATAACCACGC |
| Mouse STING (MNase)#3 | R | GGACCTGGACTTCCCTTCAT |
| Mouse STING (MNase)#4 | F | GGCGTGGTTATTTCCCCGAA |
| Mouse STING (MNase)#4 | R | GGGGAGGGGTTAGACAGGAG |
| Mouse STING (MNase)#5 | F | GCTTTGGCAGGAAACACCAAA |
| Mouse STING (MNase)#5 | R | AACTGCAACTCAGCTCGCTT |
| Mouse STING (ChIP)#1 | F | GCCAGATGGCTAGCAGGGAA |
| Mouse STING (ChIP)#1 | R | TGGGTATCAGGGATCCAACAC |
| Mouse STING (ChIP)#2 | F | TTTCGGGGAAATAACCACGC |
| Mouse STING (ChIP)#2 | R | GGACCTGGACTTCCCTTCAT |
| Mouse STING (ChIP)#3 | F | GGCGTGGTTATTTCCCCGAA |
| Mouse STING (ChIP)#3 | R | GGGGAGGGGTTAGACAGGAG |
| Mouse STING (ChIP)#4 | F | GCTTTGGCAGGAAACACCAAA |
| Mouse STING (ChIP)#4 | R | AACTGCAACTCAGCTCGCTT |
| Human ISG15 | F | AATGCGACGAACCTC |
| Human ISG15 | R | GCTCACTTGCTGCTT |
| Human NCF2 | F | ACTGCCTGACTCTGTGGT |
| Human NCF2 | R | ACTTGGCTGCCTTTCTTA |
| Human IRF7 | F | TACCTGTCACCCTCCCC |
| Human IRF7 | R | GTCCCACCACCTTCTGC |
| Human KLF4 | F | CTGAGCGGGCGAATTTCCATC |
| Human KLF4 | R | CGGGCTGCGGCAAAACCTACA |
| Human ZC3HAV1 | F | GATGGACAGAAAGGTG |
| Human ZC3HAV1 | R | CGATGTGAAGAAGGAG |
| Human RSAD2 | F | CGGAACAGATCAAAGCACT |
| Human RSAD2 | R | TTAGATTCAGGCACCAAGC |
| Human ACTIN | F | TCACCAACTGGGACGACAT |
| Human ACTIN | R | ATCTGGGTCATCTTCTCGC |
| Human TFAM | F | CGCTCCCCCTTCAGTTTTGT |
| Human TFAM | R | CCAACGCTGGGCAATTCTTC |
| Human BRD4 | F | TGCTGACGTCCGATTGATGT |
| Human BRD4 | R | TCGAACACATCCTGGAGCTTG |
| Human Trp53bp1 | F | CAAAGAATTCTGGACTGGCAACCC |
| Human Trp53bp1 | R | TCCAGGAAGTTCTGCTGTTGGTC |
| Human BRD4 (shRNA)#1 | F | CCGGCAGTGACAGTTCGACTGATGACTCGAGTCATCAGTCGAACTGTCACTGTTTTTG |
| Human BRD4 (shRNA)#1 | R | AATTCAAAAACAGTGACAGTTCGACTGATGACTCGAGTCATCAGTCGAACTGTCACTG |
| Human BRD4 (shRNA)#2 | F | CCGGCCTGGAGATGACATAGTCTTACTCGAGTAAGACTATGTCATCTCCAGGTTTTTG |
| Human BRD4 (shRNA)#2 | R | AATTCAAAAACCTGGAGATGACATAGTCTTACTCGAGTAAGACTATGTCATCTCCAGG |
| Human Trp53bp1 (shRNA)#1 | F | CCGGCCCTTGTTCAGGACAGTCTTTCTCGAGAAAGACTGTCCTGAACAAGGGTTTTTG |
| Human Trp53bp1 (shRNA)#1 | R | AATTCAAAAACCCTTGTTCAGGACAGTCTTTCTCGAGAAAGACTGTCCTGAACAAGGG |
| Human Trp53bp1 (shRNA)#2 | F | CCGGGATACTCCTTGCCTGATAATTCTCGAGAATTATCAGGCAAGGAGTATCTTTTTG |
| Human Trp53bp1 (shRNA)#2 | R | AATTCAAAAAGATACTCCTTGCCTGATAATTCTCGAGAATTATCAGGCAAGGAGTATC |
| Human NC (shRNA) | F | CCGGAAGCTGGAGTACAACTACAACCTCGAGGTTGTAGTTGTACTCCAGCTTTTTTTG |
| Human NC (shRNA) | R | AATTCAAAAAAAGCTGGAGTACAACTACAACCTCGAGGTTGTAGTTGTACTCCAGCTT |